Associate Director, Medical Communications and Publications
Alnylam Pharmaceuticals
Summary
The Associate Director, Medical Publications – TTR Franchise supports the strategic development and execution of the global medical publication plan for Alnylam's transthyretin amyloidosis (TTR) franchise. Reporting to the Director, Medical publications – TTR Franchise, this role contributes to the planning, coordination, and delivery of high-impact publications supporting Alnylam's medical strategy across cardiomyopathy and neuropathy programs.
Job description
Overview
The Associate Director, Medical Publications – TTR Franchise supports the strategic development and execution of the global medical publication plan for Alnylam's transthyretin amyloidosis (TTR) franchise. Reporting to the Director, Medical publications – TTR Franchise, this role contributes to the planning, coordination, and delivery of high-impact publications supporting Alnylam's medical strategy across cardiomyopathy and neuropathy programs.
As part of the Scientific Communications organization within Medical Affairs, the Associate Director partners closely with cross-functional stakeholders including Medical Directors, Clinical Development, Biostatistics, Scientific Communications, Legal, and Commercial teams to develop a global publication strategy, and ensure timely, accurate, and compliant dissemination of clinical and scientific data though peer-reviewed publications and presentations at major scientific congresses.
This is a highly collaborative and visible role requiring strong scientific expertise, operational excellence, and the ability to manage complex publication activities in a global matrixed environment.
Key Responsibilities
- Support the development and execution of the global TTR publication strategy aligned with medical affairs objectives and franchise priorities.
- Independently lead assigned components of the global publication plan across the lifecycle of evidence generation, including abstracts, posters, oral presentations, manuscripts, and plain language summaries.
- Proactively partner with Medical Directors, Clinical Development, and Biostatistics teams to identify publication opportunities aligned with strategic priorities.
- Coordinate cross-functional publication planning activities and contribute to Publication Working Group (PWG) operations.
- Collaborate with external authors, investigators, and key opinion leaders to support development and delivery of scientific publications.
- Provide direction to medical writing agencies and publication vendors to ensure high-quality and timely execution of deliverables.
- Ensure all publication activities comply with GPP, GPCAP, ICMJE criteria, and internal governance requirements.
- Support maintenance of publication timelines, trackers, and documentation within publications management systems.
- Represent Medical Publications in cross-functional discussions supporting evidence dissemination planning.
- Support Publication Steering Committees and Publication Planning Workshops where applicable.
- Lead and mentor junior publication team members as needed and foster a culture of scientific excellence and integrity.
- Demonstrate alignment with Alnylam core values in all internal and external interactions.
- Occasional travel (approx. 5 times annually) required to represent Alnylam at major congresses or attend company events
Qualifications
- PhD (preferred) or PharmD/MD with 5+ years of experience in the pharmaceutical/biotech industry, or medical communications agency.
- ISMPP Certified Medical Publication Professional (CMPP) certification – preferred.
- Prior medical affairs, medical communications, publications, agency and/or KOL management experience – required.
- Prior experience in rare disease, cardiology, neurology or RNA-based therapeutics – preferred.
- Experience supporting publication strategy and execution for a complex, global program – required.
- Strong working knowledge of GPP, GPCAP, ICMJE criteria, and industry best practices for publications – required.
- Demonstrated ability to work effectively in a cross-functional, matrixed environment – required.
- Excellent verbal and written communication skills; experience and high level of comfort interacting with scientific experts and senior stakeholders – required.
- Team management experience – preferred.
Requirements
- PhD (preferred) or PharmD/MD with 5+ years of experience in the pharmaceutical/biotech industry, or medical communications agency
- ISMPP Certified Medical Publication Professional (CMPP) certification – preferred
- Prior medical affairs, medical communications, publications, agency and/or KOL management experience – required
- Prior experience in rare disease, cardiology, neurology or RNA-based therapeutics – preferred
- Experience supporting publication strategy and execution for a complex, global program – required
- Strong working knowledge of GPP, GPCAP, ICMJE criteria, and industry best practices for publications – required
- Demonstrated ability to work effectively in a cross-functional, matrixed environment – required
- Excellent verbal and written communication skills; experience and high level of comfort interacting with scientific experts and senior stakeholders – required
- Team management experience – preferred
Benefits
- Medical, Dental & Vision
- Life & Disability Insurance
- Lifestyle Reimbursement Program
- Flexible Spending Accounts
- Health Savings Accounts
- 401(k) Matching
- Paid Time Off
- Wellness Days
- Holidays
- Company Recharge Breaks
- Family Resources
- Family Leave
Company overview
Alnylam Pharmaceuticals is a pioneering American biopharmaceutical company and the global leader in RNA interference (RNAi) therapeutics. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam has revolutionized the field of genetic medicine by developing innovative treatments that 'silence' disease-causing genes. The company achieved a historic milestone in 2018 with the approval of Onpattro (patisiran), the world's first RNAi therapeutic, which treats hereditary transthyretin-mediated amyloidosis. Since then, Alnylam has successfully commercialized five additional RNAi medicines targeting rare genetic disorders including acute hepatic porphyria, primary hyperoxaluria type 1, and transthyretin amyloidosis. With over 2,100 employees worldwide, Alnylam maintains a robust pipeline of investigational therapies across genetic medicines, cardiometabolic diseases, and hepatic infectious diseases. The company's groundbreaking work has established RNAi as a clinically validated therapeutic platform, earning recognition as one of the most innovative biopharmaceutical companies and consistently ranking as a top employer in the life sciences industry.